X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (247) 247
Conference Proceeding (67) 67
Publication (28) 28
Book Review (8) 8
Book / eBook (3) 3
Book Chapter (2) 2
Report (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (126) 126
hematology (119) 119
humans (114) 114
male (75) 75
female (74) 74
multiple myeloma (73) 73
middle aged (67) 67
aged (62) 62
adult (51) 51
medical and health sciences (42) 42
medicin och hälsovetenskap (42) 42
oncology (37) 37
multiple myeloma - drug therapy (32) 32
survival (32) 32
clinical medicine (27) 27
klinisk medicin (27) 27
multiple myeloma - mortality (26) 26
aged, 80 and over (23) 23
antineoplastic combined chemotherapy protocols - therapeutic use (23) 23
transplantation (23) 23
therapy (22) 22
chemotherapy (21) 21
prognosis (21) 21
hematologi (19) 19
multiple myeloma - therapy (19) 19
thalidomide (19) 19
bortezomib (18) 18
multiple myeloma - diagnosis (17) 17
treatment outcome (17) 17
multiple myeloma - genetics (15) 15
vitamin b 12 - blood (15) 15
abridged index medicus (14) 14
cancer (14) 14
care and treatment (14) 14
dexamethasone (14) 14
survival rate (14) 14
medicine (13) 13
melphalan (13) 13
multiple myeloma - pathology (13) 13
disease-free survival (12) 12
medicin (12) 12
quality of life (12) 12
analysis (11) 11
denmark (11) 11
myeloma (11) 11
survival analysis (11) 11
antineoplastic combined chemotherapy protocols - adverse effects (10) 10
clinical trials (10) 10
multiple-myeloma (10) 10
recurrence (10) 10
soil (10) 10
transplantation, autologous (10) 10
degradation (9) 9
expression (9) 9
hematopoietic stem cell transplantation (9) 9
melphalan - administration & dosage (9) 9
retrospective studies (9) 9
risk (9) 9
soils (9) 9
sorption (9) 9
stem cell transplantation (9) 9
stem-cell transplantation (9) 9
thalidomide - administration & dosage (9) 9
cancer and oncology (8) 8
cancer och onkologi (8) 8
cobalamin (8) 8
competitive adsorption (8) 8
dexamethasone - administration & dosage (8) 8
dose-response relationship, drug (8) 8
follow-up studies (8) 8
genetic aspects (8) 8
hematology, oncology and palliative medicine (8) 8
lenalidomide (8) 8
medical research (8) 8
medicine, experimental (8) 8
multiple myeloma - complications (8) 8
stem cells (8) 8
thalidomide - therapeutic use (8) 8
transcobalamins - analysis (8) 8
vitamin b 12 - metabolism (8) 8
adolescent (7) 7
bone marrow (7) 7
development and progression (7) 7
genes (7) 7
goethite (7) 7
high-dose therapy (7) 7
immunology (7) 7
kaplan-meier estimate (7) 7
melphalan - therapeutic use (7) 7
multiple myeloma - blood (7) 7
multiple myeloma - metabolism (7) 7
patients (7) 7
quality-of-life (7) 7
remission induction (7) 7
risk factors (7) 7
time factors (7) 7
animals (6) 6
antineoplastic agents - administration & dosage (6) 6
antineoplastic agents - therapeutic use (6) 6
antineoplastic combined chemotherapy protocols - administration & dosage (6) 6
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 04/2016, Volume 374, Issue 17, pp. 1621 - 1634
The addition of the oral proteasome inhibitor ixazomib to a regimen of lenalidomide plus dexamethasone led to a significant prolongation of progression-free... 
SUPERIORITY | MEDICINE, GENERAL & INTERNAL | CARFILZOMIB | RANDOMIZED PHASE-3 | THERAPY | PROTEASOME INHIBITOR MLN9708 | QUALITY-OF-LIFE | BORTEZOMIB | THALIDOMIDE | ANTITUMOR-ACTIVITY | TRANSPLANTATION | Glycine - analogs & derivatives | Glycine - adverse effects | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Boron Compounds - administration & dosage | Thalidomide - analogs & derivatives | Multiple Myeloma - drug therapy | Exanthema - chemically induced | Aged, 80 and over | Adult | Glycine - administration & dosage | Dexamethasone - administration & dosage | Double-Blind Method | Administration, Oral | Kaplan-Meier Estimate | Proportional Hazards Models | Thrombocytopenia - chemically induced | Thalidomide - administration & dosage | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Quality of Life | Boron Compounds - adverse effects | Aged | Care and treatment | Dosage and administration | Dexamethasone | Multiple myeloma | Thrombocytopenia | Inhibitor drugs | Risk groups | Drug therapy | Peripheral neuropathy | Survival | Patients | Drug dosages | Proteasome inhibitors | Quality of life | Index Medicus | Abridged Index Medicus | Clinical Medicine | Medical and Health Sciences | Klinisk medicin | Cancer and Oncology | Medicin och hälsovetenskap | Cancer och onkologi
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 09/2015, Volume 373, Issue 13, pp. 1207 - 1219
Journal Article
Blood, ISSN 0006-4971, 10/2016, Volume 128, Issue 14, pp. 1821 - 1828
Journal Article
Blood, ISSN 0006-4971, 08/2011, Volume 118, Issue 5, pp. 1239 - 1247
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 11, pp. 1195 - 1206
Journal Article
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 2015, Volume 21, Issue 12, pp. 2039 - 2051
Abstract In contrast to the upfront setting in which the role of high-dose therapy with autologous hematopoietic cell transplantation (HCT) as consolidation of... 
Hematology, Oncology and Palliative Medicine | Stem cell transplantation | Myeloma | Salvage therapy | BORTEZOMIB-THALIDOMIDE-DEXAMETHASONE | COMBINATION THERAPY | LENALIDOMIDE PLUS DEXAMETHASONE | AUTOLOGOUS TRANSPLANTATION | FOLLOW-UP | RISK | IMMUNOLOGY | TRANSPLANTATION | ALLOGENEIC TRANSPLANTATION | MAINTENANCE | RANDOMIZED PHASE-III | HEMATOLOGY | LOW-DOSE DEXAMETHASONE | Myeloablative Agonists - therapeutic use | Recurrence | Humans | Antibodies, Monoclonal - therapeutic use | Multiple Myeloma - immunology | Transplantation, Autologous | Bone Marrow Transplantation - methods | Remission Induction | Proteasome Inhibitors - therapeutic use | Transplantation, Homologous | Randomized Controlled Trials as Topic | Multiple Myeloma - pathology | Multiple Myeloma - therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Hematopoietic Stem Cell Transplantation - methods | Transplantation Conditioning - methods | Salvage Therapy - methods | Immunologic Factors - therapeutic use | Relapse | Multiple myeloma | Bone marrow | Clinical trials | Transplantation | Conferences and conventions | Hematopoietic stem cells | Trade and professional associations | Diseases | Index Medicus | Clinical Medicine | Hematologi | Medical and Health Sciences | Hematology | Klinisk medicin | Medicin och hälsovetenskap
Journal Article
Gene, ISSN 0378-1119, 02/2018, Volume 644, pp. 80 - 86
A Drug Response Prediction (DRP) score was developed based on gene expression profiling (GEP) from cell lines and tumor samples. Twenty percent of high-risk... 
Drug response prediction | High-risk | Multiple myeloma | CONSENSUS | BORTEZOMIB | THALIDOMIDE | WORKING GROUP | THERAPY | GENES | GENETICS & HEREDITY | REFRACTORY MYELOMA | STEM-CELL TRANSPLANTATION | EXPRESSION SIGNATURE | STRATIFICATION | Index Medicus
Journal Article
Acta Haematologica, ISSN 0001-5792, 05/2015, Volume 133, Issue 4, pp. 372 - 380
Journal Article
JOURNAL OF NUCLEAR MEDICINE, ISSN 0161-5505, 02/2003, Volume 44, Issue 2, pp. 177 - 183
Changes in the amount and distribution of amyloid lesions have been difficult to monitor because they can usually be demonstrated only by evident symptoms or... 
P COMPONENT | amyloidosis | scintigraphy | TC-99M APROTININ | LIVER | Tc-99m-aprotinin | SYSTEMIC AMYLOIDOSIS | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
Journal Article
European Journal of Haematology, ISSN 0902-4441, 09/2008, Volume 81, Issue 3, pp. 170 - 176
Journal Article
Haematologica, ISSN 0390-6078, 01/2013, Volume 98, Issue 1, pp. 87 - 94
Journal Article